IL279183A - Method for administering a therapeutically effective amount of 5-[[4-[2-[5-(1-hydroxyethyl)pyridin-2-yl]ethoxy]phenyl]methyl]-1, 3-thiazolidine-2, 4-dione - Google Patents

Method for administering a therapeutically effective amount of 5-[[4-[2-[5-(1-hydroxyethyl)pyridin-2-yl]ethoxy]phenyl]methyl]-1, 3-thiazolidine-2, 4-dione

Info

Publication number
IL279183A
IL279183A IL279183A IL27918320A IL279183A IL 279183 A IL279183 A IL 279183A IL 279183 A IL279183 A IL 279183A IL 27918320 A IL27918320 A IL 27918320A IL 279183 A IL279183 A IL 279183A
Authority
IL
Israel
Prior art keywords
thiazolidine
dione
pyridin
ethoxy
hydroxyethyl
Prior art date
Application number
IL279183A
Other languages
English (en)
Hebrew (he)
Inventor
Pedemonte Marc Martinell
Lalanza Maria Pilar Pizcueta
Laguna Guillem Pina
Uwe Meya
Alan Bye
Original Assignee
Minoryx Therapeutics S L
Pedemonte Marc Martinell
Lalanza Maria Pilar Pizcueta
Laguna Guillem Pina
Uwe Meya
Alan Bye
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Minoryx Therapeutics S L, Pedemonte Marc Martinell, Lalanza Maria Pilar Pizcueta, Laguna Guillem Pina, Uwe Meya, Alan Bye filed Critical Minoryx Therapeutics S L
Publication of IL279183A publication Critical patent/IL279183A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
IL279183A 2018-06-06 2020-12-03 Method for administering a therapeutically effective amount of 5-[[4-[2-[5-(1-hydroxyethyl)pyridin-2-yl]ethoxy]phenyl]methyl]-1, 3-thiazolidine-2, 4-dione IL279183A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP18382398 2018-06-06
PCT/IB2019/054743 WO2019234689A1 (en) 2018-06-06 2019-06-06 Method of administering a therapeutically effective amount of 5-[[4-[2-[5-(1-hydroxyethyl)pyridin-2-yl]ethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione

Publications (1)

Publication Number Publication Date
IL279183A true IL279183A (en) 2021-01-31

Family

ID=62716009

Family Applications (1)

Application Number Title Priority Date Filing Date
IL279183A IL279183A (en) 2018-06-06 2020-12-03 Method for administering a therapeutically effective amount of 5-[[4-[2-[5-(1-hydroxyethyl)pyridin-2-yl]ethoxy]phenyl]methyl]-1, 3-thiazolidine-2, 4-dione

Country Status (14)

Country Link
US (1) US20210308113A1 (https=)
EP (1) EP3801516A1 (https=)
JP (1) JP7549344B2 (https=)
KR (1) KR20210031435A (https=)
CN (1) CN112512524A (https=)
AU (1) AU2019283649A1 (https=)
BR (1) BR112020024917A2 (https=)
CA (1) CA3102407A1 (https=)
CL (1) CL2020003162A1 (https=)
EA (1) EA202092953A1 (https=)
IL (1) IL279183A (https=)
MX (1) MX2020013181A (https=)
SG (1) SG11202012045UA (https=)
WO (1) WO2019234689A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130158077A1 (en) 2011-12-19 2013-06-20 Ares Trading S.A. Pharmaceutical compositions
FI3801515T3 (fi) 2018-06-06 2025-05-27 Minoryx Therapeutics S L 5-[[4-[2-[5-(1-hydroksietyyli)pyridin-2-yyli]etoksi]fenyyli]metyyli]-1,3-tiatsolidiini-2,4-dionia ja sen suoloja käytettäviksi mitokondriosairauksien hoidossa
EP4642456A1 (en) 2022-12-28 2025-11-05 Minoryx Therapeutics S.L. Optimized dosing of leriglitazone
MX2025013233A (es) 2023-05-09 2026-02-03 Minoryx Therapeutics S L Formas polimorficas y formulaciones de leriglitazona

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3703058A1 (en) * 2005-11-29 2020-09-02 Children's Hospital Medical Center A method of selecting a medication for a patient
US20140114676A1 (en) * 2012-10-23 2014-04-24 Theranos, Inc. Drug Monitoring and Regulation Systems and Methods
EP3125888B1 (en) * 2014-04-02 2018-05-23 Minoryx Therapeutics S.L. 2,4-thiazolidinedione derivatives in the treatment of central nervous system disorders
EP3559010B1 (en) 2016-12-23 2022-06-08 Minoryx Therapeutics S.L. Process for preparing 5-[[4-[2-[5-(1-hydroxyethyl)-2-pyridinyl]ethoxy]phenyl]methyl]-2,4-thiazolidinedione and salts thereof

Also Published As

Publication number Publication date
CN112512524A (zh) 2021-03-16
WO2019234689A1 (en) 2019-12-12
BR112020024917A2 (pt) 2021-03-09
CL2020003162A1 (es) 2021-07-02
EA202092953A1 (ru) 2021-04-12
MX2020013181A (es) 2021-02-26
AU2019283649A1 (en) 2021-01-07
CA3102407A1 (en) 2019-12-12
SG11202012045UA (en) 2021-01-28
EP3801516A1 (en) 2021-04-14
KR20210031435A (ko) 2021-03-19
JP7549344B2 (ja) 2024-09-11
JP2021527045A (ja) 2021-10-11
US20210308113A1 (en) 2021-10-07

Similar Documents

Publication Publication Date Title
IL279183A (en) Method for administering a therapeutically effective amount of 5-[[4-[2-[5-(1-hydroxyethyl)pyridin-2-yl]ethoxy]phenyl]methyl]-1, 3-thiazolidine-2, 4-dione
CY1125531T1 (el) Μεθοδος παρασκευης της 5-[[4-[2-[5-(1- υδροξυαιθυλ)-2-πυριδι-νυλ]αιθοξυ]φαινυλ]μεθυλ]- 2,4-θειαζολιδινεδιονη και των αλατων της
IL279186A (en) Use of 5-[[4-[2-[5-acetylpyridin-2-yl]ethoxy]benzyl]-1, 3-thiazolidine-2, 4-dione and their salts
PT3548026T (pt) 5-[[4-[2-[5-(1-hidroxietil)piridin-2-il]etoxi]fenil]metil]-1,3-tiazolidina-2,4-diona para tratar a doença do fígado gordo não alcoólico
WO2012047966A4 (en) Compositions and methods for treating ocular edema, neovascularization and related diseases
RU2011133833A (ru) Способы лечения синдрома сосудистой утечки
JP2014528486A5 (https=)
RU2018138707A (ru) Замещенные гетероарилом пиридины и способы применения
WO2005080358A3 (en) Rosiglitazone phosphate and polymorphic forms
FI3511319T3 (fi) Lysiinispesifisen demetylaasi-1:n inhibiittoreita
JP2013516483A5 (https=)
WO2009015812A3 (de) Prodrugs des 2-amino-6- ( { [2- (4-chlorphenyl) -1, 3-thiaz0l-4-yl] methyl}thio) -4- [4- ( 2 -hydroxyethoxy) phenyl] pyridin-3, 5-dicarbonitrils
LT3801515T (lt) 5-[[4-[2-[5-(1-hidroksietil)piridin-2-il]etoksi]fenil]metil]-1,3-tiazolidin-2,4-dionas ir jo druskos, skirti mitochondrinių ligų gydymui
SI3038622T1 (en) Heterocyclic compounds and methods of use
NZ629636A (en) Liver x receptor (lxr) modulators for the treatment of dermal diseases, disorders and conditions
RU2017127484A (ru) Соединение, фармацевтическая композиция, лекарственное средство
RU2015126293A (ru) Производные тиазола в качестве ингибиторов тирозинкиназы брутона
HK40050840A (en) Method of administering a therapeutically effective amount of 5-[[4-[2-[5-(1-hydroxyethyl)pyridin-2-yl]ethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione
PL3679016T3 (pl) Postacie stałe 2-(5-(4-(2-morfolinoetoksy)fenylo)pirydyn-2-ylo)-n-benzyloacetamidu
JP2013507397A5 (https=)
JP2019521137A5 (https=)
IL188175A0 (en) 2-n-(5-[[4-(2-methyl-2-pyridinylamino)ethoxy] phenyl] methyl]-2,4-thiazolidinedione)butanedioic acid, methods of preparation and compositions with rosiglitazone maleate
AU2003269483A1 (en) Phosphoric acid salt of 5-((4-(2-(methyl-2-pyridinylamino) ethoxy) phenyl) methyl)- 2,4-thiazolidinedione
PL385697A1 (pl) Sól 5-[[4-[2-(metylo-2-pirydynyloamino)etoksy]fenylo]metylo]-2, 4-tiazolidynodionu z kwasem 1, 5-naftalenodisulfonowym i sposób jej wytwarzania
HK40025190A (en) Solid forms of 2-(5-(4-(2-morpholinoethoxy)phenyl)pyridin-2-yl)-n-benzylacetamide